Navigation Links
The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
Date:11/9/2007

Mark Lanier, winner of nation's first Vioxx trial, hails settlement as 'the

right thing to do'

HOUSTON, Nov. 9 /PRNewswire/ -- Attorneys from The Lanier Law Firm are announcing a nationwide settlement agreement with pharmaceutical giant Merck & Co. Inc. (NYSE: MRK) that should resolve at least 85% of the personal injury lawsuits in the U.S. over Vioxx, the company's controversial pain medication.

(Photo: http://www.newscom.com/cgi-bin/prnh/20060623/DAF008)

"This was simply the right thing to do, and we're grateful that the people at Merck recognized that it was the right thing to do," says Houston attorney Mark Lanier, founder of The Lanier Law Firm and lead counsel in the nation's first Vioxx trial. "A lot of lawyers worked hard to get this settlement, which will help thousands of our clients and every other injured Vioxx patient in the United States."

Mr. Lanier has been a national leader in Vioxx litigation since winning a $253 million verdict in the country's first Vioxx lawsuit in August 2005. That case -- decided in favor of the wife of a former marathon runner who died after taking Vioxx for only eight months -- stands as the largest Vioxx verdict in history.

Today's settlement with Whitehouse Station, N.J.-based Merck marks the end of a series of legal battles that began after the company withdrew Vioxx from store shelves in September 2004. Vioxx was pulled from the market after a study revealed that users of the drug were more susceptible to heart attacks and strokes than people using other pain medications.

To interview Mr. Lanier about the Vioxx settlement, please co
'/>"/>

SOURCE The Lanier Law Firm
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
(Date:9/17/2014)... (HealthDay News) -- A blood test that measures DNA ... a better assessment of the state of a man,s ... routinely, this blood test could reveal when treatment ... promoting tumor growth, the researchers suggested. "Our study ... advanced prostate cancer and often initially very effective started ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Why are Asian Americans at higher risk of developing ... develop the disease at lower body weights? One part ... traditional high-fiber, low-fat Asian diets to current westernized diets, ... heritage, says George King, M.D., Senior Vice President and ... senior author of the study. , A Joslin randomized ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace is ... on molecular diagnostics for conditions such as infectious diseases, ... IVD market value is projected to be worth around ... major drivers of the market’s growth include the shift ... by the explosion for raid and minimally-invasive diagnostic tools; ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... countrymen safe drinking water within a matter of four ... // to make this possible. Most people living in ... water. ,Inaugurating a conference of ministers ... sanitation in states and union territories, the prime minister ...
... speak hundred words, these non-verbal communications is also found ... been a major cause of distress and may lead ... School of Medicine along with his colleagues from Indianapolis ... as reported in the Journal of General Internal Medicine ...
... Journal of the American Medical Association has published that ... continue their anti-depressant medication to avoid a relapse.// ... University and Massachusetts General Hospital, where 201 pregnant women ... not depressed during the course of the study. According ...
... Michael Horwin have launched the SV40 Cancer Foundation in ... 1999 from an SV40 positive brain tumor. // The ... encourage independent research and to facilitate clinical improvements." ... brain tumor that was caused by an active SV40 ...
... there is a definite link between disease and higher death rates ... the // data of 1,347 people aged about 56 in the ... ,The IQ of the volunteers was assessed by a written test ... scores follow a social trend and that the poorest socioeconomic groups ...
... revealed that a Husband’s comforting touch can be a ... the study, those who establish instant communication by reaching ... A handy tip on how human touch can alleviate ... feature of the study revealed that relief from a ...
Cached Medicine News:Health News:Safe Drinking Water To Be Made Available 2Health News:Pregnancy Not An Antidote To Depression 2Health News:Handy Touch - A Wand to Bust Stressful Situations 2
(Date:9/17/2014)... An analysis done by the CVS Health ... a new and expensive treatment for Hepatitis C introduced ... several months (May through August 2014) there has been ... This suggests another surge of patients will begin therapy ... efficacy and shorter duration are introduced in the Fall. ...
(Date:9/17/2014)... Utah , Sept. 17, 2014  NuView ... exclusive global licensing and collaboration agreement with Otsuka ... commercialize NuView,s investigative genomic-based diagnostic biomarker to detect ... also includes all other future diagnostic-imaging applications. NuView ... in-vivo therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... LAWRENCEVILLE, N.J. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... that details how to implement GS1 Standards to ... (DSCSA), and enhance patient safety and security in ... Applying GS1 Standards to U.S. Pharmaceutical Supply ... Chain Security Act , was developed in ...
Breaking Medicine Technology:CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
... - Opexa,Therapeutics, Inc. (NASDAQ:OPXA), a company involved ... today,announced positive top-line data in an open-label ... T-cell vaccine,Tovaxin(TM), for multiple sclerosis (MS). In ... remitting (RRMS),and secondary progressive (SPMS) subjects, Tovaxin ...
... 2007 - “In anaplastic,astrocytoma, AP 12009 as a ... Wong, M.D., Stanford,University, California, U.S.A. commented on the ... 12009, under development,by Antisense Pharma. Prof. Wong discussed ... session on central nervous system tumors,at the 43rd ...
Cached Medicine Technology:Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 2Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 4Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 5Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 2Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 3Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 4
... the most powerful isolated ESU on the market ... is the only ESU that allows the surgeon ... with a standard ES pencil. Excalibur Plus PC ... necessary voltage for smooth cutting through various impedance ...
High performance capabilities in a multipurpose generator, blended cut modes, simultaneous independent coagulation, low voltage coagulation, valleylab REM safety substantially reduces the risk of pat...
The Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Lorgnette pinhole occluder...
Medicine Products: